View in EDS

Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention.

Saved in:
Bibliographic Details
Title: Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention.
Authors: Thiam-Diouf A; HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., E3-300, PO Box 19024, Seattle, WA 98109, United States. Electronic address: Arame.Thiam@bcm.edu., Metch B; Fred Hutchinson Cancer Research Center, Statistical Center for HIV/AIDS Research and Prevention (SCHARP), United States. Electronic address: bmetch@fredhutch.org., Sharpe C; University of British Columbia, 2329 West Mall, Vancouver, BC V6T 1Z4, Canada. Electronic address: cameronjaysharpe@gmail.com., Mulugeta R; Yale University, New Haven, CT 06520, United States. Electronic address: robel.mulugeta@yale.edu., Andrasik MP; HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., E3-300, PO Box 19024, Seattle, WA 98109, United States. Electronic address: mandrasik@fredhutch.org.
Source: Vaccine [Vaccine] 2018 Feb 21; Vol. 36 (9), pp. 1235-1242.
Publication Type: Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-2518
DOI:10.1016/j.vaccine.2017.11.032